Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III
Sunday, November 8, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Helena Marzo-Ortega, PhD – Leeds Teaching Hospitals Trust
9:00 AM – 11:00 AM ET
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study Vibeke Strand, MD – Stanford University School of Medicine
9:00 AM – 11:00 AM ET
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
9:00 AM – 11:00 AM ET
Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials Peter Nash, MBBS, FRACP – Griffith University
9:00 AM – 11:00 AM ET
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis Runsheng Wang, MD, MHS – Columbia University Irving Medical Center
9:00 AM – 11:00 AM ET
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study Walter P. Maksymowych, MD, FRCPC – University of Alberta
9:00 AM – 11:00 AM ET
What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial Philip S. Helliwell, PhD, DM, FRCP, MA – University of Leeds
9:00 AM – 11:00 AM ET
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study Kurt de Vlam, MD, PhD – university hospitals leuven
9:00 AM – 11:00 AM ET
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial Vibeke Strand, MD – Stanford University School of Medicine
9:00 AM – 11:00 AM ET
Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs Vibeke Strand, MD – Stanford University School of Medicine
9:00 AM – 11:00 AM ET
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis Laura C. Coates, PhD, MBChB – University of Oxford
9:00 AM – 11:00 AM ET
Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials Gerd R. Burmester, MD – Charité – University Medicine Berlin
9:00 AM – 11:00 AM ET
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension Joseph F. Merola, MD, MSc – Brigham and Women's Hospital
9:00 AM – 11:00 AM ET
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage Laura C. Coates, PhD, MBChB – University of Oxford
9:00 AM – 11:00 AM ET
The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis Mark Siderius, BSc, MSc – University Medical Centre Groningen
9:00 AM – 11:00 AM ET
Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs Philip J. Mease, MD – Seattle Rheumatology Associates
9:00 AM – 11:00 AM ET
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis Adela Castro, MD – UT Southwestern
9:00 AM – 11:00 AM ET
Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Targeted Serum Proteomic Analysis Following Upadacitinib Treatment in Ankylosing Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue Repair Modulation Dennis McGonagle, PhD, MB, FRCPI – University of Leeds
9:00 AM – 11:00 AM ET
New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study Jean-Guillaume Letarouilly, FCPS – Lille University Hospital
9:00 AM – 11:00 AM ET
Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study Maria-Antonietta A. D'Agostino, MD, PhD, MSc – APHP, UVSQ
9:00 AM – 11:00 AM ET
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study C.A.J Michielsens, PhD – Sint Maartenskliniek
9:00 AM – 11:00 AM ET
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet Herne
9:00 AM – 11:00 AM ET
Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab Amir Jamaludin, PhD – University of Oxford
9:00 AM – 11:00 AM ET
Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation Juergen Braun, MD – Rheumazentrum Ruhrgebiet
9:00 AM – 11:00 AM ET
Impact of Ixekizumab on Work Productivity in Non-Radiographic Axial Spondyloarthritis Patients: Results from the COAST-X Trial at 52 Weeks Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study Peter Nash, MBBS, FRACP – Griffith University
9:00 AM – 11:00 AM ET
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52 Saima Chohan, MD – Arizona Arthritis & Rheumatology Associates, P.C.
9:00 AM – 11:00 AM ET
A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort Denis Poddubnyy, MD, MSc – Charité - Universitätsmedizin Berlin
9:00 AM – 11:00 AM ET
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement Atul Deodhar, MD – Oregon Health & Science University
9:00 AM – 11:00 AM ET
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors Alessandra Nerviani, MD, PhD – Queen Mary University of London
9:00 AM – 11:00 AM ET
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial Bruce Kirkham, MD – Guy's Hospital
9:00 AM – 11:00 AM ET
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life? Charlotte Baert – Rheumatology department, St-Luc university hospitals
9:00 AM – 11:00 AM ET
Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis Valeria Rios Rodriguez, MD – Charité Universitätsmedizin Berlin
